Dexcel Pharma Technologies Ltd. - 01 Oct 2021 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: 10%+ Owner
Signature: /s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
Issuer symbol: ROIV
Transactions as of: 01 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 01 Oct 2021, 17:02:10 UTC
Previous filing: 03 Jun 2021
Next filing: 26 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ROIV	Common Shares						98,809,158	01 Oct 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 643,845 common shares. Dexxon Holdings Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.